The question is one of neurology’s many enduring and intriguing debates. At the AAT-AD/PD Focus meeting, Amos Korczyn (Tel Aviv University, Israel) was clear the answer is “No”. The problematic basis for a diagnosis of mild cognitive impairment, its uncertain prognostic implications, and the adverse impact it may have on patients makes the concept unsuited for clinical use. Do you agree?
Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.
1. Goldman AG, Litvan I. Minerva Med 2011;102:441-59
2. Weil RS, et al. Curr Neurol Neurosci 2018;18:17
3. Palavra N, et al. Neurology Research Int 2013;ID 576091
4. Cammisuli DM, et al. Front. Aging Neurosci; 2019 Nov 8